IGF1 and cancer: Moreover, the obtained data suggested that the combination therapy is more efficient compared to everolimus administration alone, since octreotide LAR can decrease IGF-1 levels in patients with malignant tumors, thus reducing everolimus resistance (IGF-1 upregulation could lead to it) [201].